Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Dec 15;101(12):1995-2004.
doi: 10.1038/sj.bjc.6605411. Epub 2009 Nov 10.

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

D A Reardon  1 , G Dresemann, S Taillibert, M Campone, M van den Bent, P Clement, E Blomquist, L Gordower, H Schultz, J Raizer, P Hau, J Easaw, M Gil, J Tonn, A Gijtenbeek, U Schlegel, P Bergstrom, S Green, A Weir, Z Nikolova
Affiliations
Clinical Trial

Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma

D A Reardon et al. Br J Cancer. .

Abstract

Background: We evaluated the efficacy of imatinib mesylate in addition to hydroxyurea in patients with recurrent glioblastoma (GBM) who were either on or not on enzyme-inducing anti-epileptic drugs (EIAEDs).

Methods: A total of 231 patients with GBM at first recurrence from 21 institutions in 10 countries were enrolled. All patients received 500 mg of hydroxyurea twice a day. Imatinib was administered at 600 mg per day for patients not on EIAEDs and at 500 mg twice a day if on EIAEDs. The primary end point was radiographic response rate and secondary end points were safety, progression-free survival at 6 months (PFS-6), and overall survival (OS).

Results: The radiographic response rate after centralised review was 3.4%. Progression-free survival at 6 months and median OS were 10.6% and 26.0 weeks, respectively. Outcome did not appear to differ based on EIAED status. The most common grade 3 or greater adverse events were fatigue (7%), neutropaenia (7%), and thrombocytopaenia (7%).

Conclusions: Imatinib in addition to hydroxyurea was well tolerated among patients with recurrent GBM but did not show clinically meaningful anti-tumour activity.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Representative example of c-KIT gene amplification detected by fluorescence in situ hybridisation (FISH). High-level amplification of c-KIT (red signals) detected along with two copies of chromosome 4 centromeres (green signals).
Figure 2
Figure 2
Kaplan–Meier plots of progression-free survival (A) and overall survival (B) for patients enrolled on H2201 and H2202 studies.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Aloyz R, Grzywacz K, Xu ZY, Loignon M, Alaoui-Jamali MA, Panasci L (2004) Imatinib sensitizes CLL lymphocytes to chlorambucil. Leukemia 18: 409–414 - PubMed
    1. Apte SM, Fan D, Killion JJ, Fidler IJ (2004) Targeting the platelet-derived growth factor receptor in antivascular therapy for human ovarian carcinoma. Clin Cancer Res 10: 897–908 - PubMed
    1. Ballman KV, Buckner JC, Brown PD, Giannini C, Flynn PJ, LaPlant BR, Jaeckle KA (2007) The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol 9: 29–38 - PMC - PubMed
    1. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D (2003) Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 111: 1287–1295 - PMC - PubMed
    1. Brandes AA, Tosoni A, Spagnolli F, Frezza G, Leonardi M, Calbucci F, Franceschi E (2008) Disease progression or pseudoprogression after concomitant radiochemotherapy treatment: pitfalls in neurooncology. Neuro Oncol 10: 361–367 - PMC - PubMed

Publication types

MeSH terms